Waldron Private Wealth LLC Buys 426 Shares of Danaher Co. (NYSE:DHR)

Waldron Private Wealth LLC increased its stake in Danaher Co. (NYSE:DHR) by 10.8% during the third quarter, Holdings Channel.com reports. The firm owned 4,369 shares of the conglomerate’s stock after purchasing an additional 426 shares during the quarter. Waldron Private Wealth LLC’s holdings in Danaher were worth $1,215,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of DHR. Vanguard Group Inc. boosted its holdings in shares of Danaher by 7.4% in the first quarter. Vanguard Group Inc. now owns 60,107,030 shares of the conglomerate’s stock valued at $15,009,928,000 after purchasing an additional 4,163,657 shares during the period. Legal & General Group Plc boosted its holdings in shares of Danaher by 2.4% in the second quarter. Legal & General Group Plc now owns 5,964,031 shares of the conglomerate’s stock valued at $1,490,112,000 after purchasing an additional 139,989 shares during the period. Capital Research Global Investors raised its stake in Danaher by 1.0% in the first quarter. Capital Research Global Investors now owns 5,125,470 shares of the conglomerate’s stock worth $1,279,932,000 after buying an additional 52,679 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in Danaher by 2.6% in the second quarter. Dimensional Fund Advisors LP now owns 3,398,649 shares of the conglomerate’s stock worth $849,195,000 after buying an additional 85,081 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA raised its stake in Danaher by 22.7% in the second quarter. Massachusetts Financial Services Co. MA now owns 3,047,728 shares of the conglomerate’s stock worth $761,475,000 after buying an additional 563,546 shares in the last quarter. 79.05% of the stock is owned by institutional investors.

Danaher Trading Down 3.8 %

Shares of NYSE:DHR traded down $10.23 during midday trading on Tuesday, hitting $261.86. 3,287,212 shares of the stock were exchanged, compared to its average volume of 2,717,444. The business’s 50-day moving average price is $270.82 and its 200 day moving average price is $260.34. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. The stock has a market capitalization of $193.96 billion, a price-to-earnings ratio of 44.23, a P/E/G ratio of 4.49 and a beta of 0.83. Danaher Co. has a 12 month low of $182.09 and a 12 month high of $281.70.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.57 by $0.15. The firm had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The business’s revenue for the quarter was down 2.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.05 EPS. Analysts predict that Danaher Co. will post 7.59 earnings per share for the current year.

Danaher Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Friday, September 27th will be given a dividend of $0.27 per share. The ex-dividend date is Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.41%. Danaher’s dividend payout ratio is presently 18.31%.

Insider Activity

In other news, SVP Brian W. Ellis sold 9,600 shares of Danaher stock in a transaction dated Thursday, July 25th. The stock was sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the completion of the sale, the senior vice president now owns 20,230 shares in the company, valued at approximately $5,566,486.80. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, SVP Brian W. Ellis sold 9,600 shares of Danaher stock in a transaction that occurred on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the sale, the senior vice president now directly owns 20,230 shares in the company, valued at $5,566,486.80. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the transaction, the senior vice president now directly owns 4,212 shares in the company, valued at approximately $1,130,374.44. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 39,659 shares of company stock valued at $11,042,433 in the last 90 days. Insiders own 11.10% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. Wells Fargo & Company assumed coverage on Danaher in a research report on Tuesday, August 27th. They set an “equal weight” rating and a $280.00 price target on the stock. StockNews.com downgraded Danaher from a “buy” rating to a “hold” rating in a research report on Tuesday, June 25th. Stifel Nicolaus upped their price target on shares of Danaher from $235.00 to $250.00 and gave the company a “hold” rating in a report on Wednesday, July 24th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $300.00 price target on shares of Danaher in a report on Friday, September 6th. Finally, Stephens initiated coverage on shares of Danaher in a report on Tuesday, October 1st. They issued an “overweight” rating and a $315.00 price target on the stock. Seven investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $282.12.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.